PROMIS NEUROSCIENCES INC. Operating Cash Flow
PROMIS NEUROSCIENCES INC. (PMN) reported Operating Cash Flow of -$22.77 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- PROMIS NEUROSCIENCES INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$10.39M.
- PROMIS NEUROSCIENCES INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$12.38M.
- PROMIS NEUROSCIENCES INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$9.28M.
- PROMIS NEUROSCIENCES INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$10.06M.
- PROMIS NEUROSCIENCES INC. net cash provided by (used in) operating activities for fiscal 2025 was -$28.12M.
- PROMIS NEUROSCIENCES INC. net cash provided by (used in) operating activities for fiscal 2024 was -$27.18M.
- PROMIS NEUROSCIENCES INC. net cash provided by (used in) operating activities for fiscal 2023 was -$10.84M.
- PROMIS NEUROSCIENCES INC. net cash provided by (used in) operating activities for fiscal 2022 was -$17.03M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$10.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$22.77M 10-Q · filed 2026-08-13 | -$32.05M derived: sum of 3 quarters · filed 2026-08-13 | -$42.11M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$12.38M 10-Q · filed 2026-05-12 | -$21.67M derived: sum of 2 quarters · filed 2026-05-12 | -$31.72M derived: sum of 3 quarters · filed 2026-05-12 | -$35.58M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$9.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$19.34M derived: sum of 2 quarters · filed 2026-03-25 | -$23.19M derived: sum of 3 quarters · filed 2026-08-13 | -$28.12M 10-K · filed 2026-03-25 |
| 2025-09-30 | -$10.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$13.91M derived: sum of 2 quarters · filed 2026-08-13 | -$18.84M 10-Q · filed 2025-11-12 | -$27.55M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$3.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$8.78M 10-Q · filed 2026-08-13 | -$17.50M derived: sum of 3 quarters · filed 2026-08-13 | -$24.17M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$4.93M 10-Q · filed 2026-05-12 | -$13.64M derived: sum of 2 quarters · filed 2026-05-12 | -$20.31M derived: sum of 3 quarters · filed 2026-05-12 | -$21.82M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$8.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$15.39M derived: sum of 2 quarters · filed 2026-03-25 | -$16.89M derived: sum of 3 quarters · filed 2026-03-25 | -$27.18M 10-K · filed 2026-03-25 |
| 2024-09-30 | -$6.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$8.18M derived: sum of 2 quarters · filed 2025-11-12 | -$18.47M 10-Q · filed 2025-11-12 | -$22.23M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$11.80M 10-Q · filed 2025-08-13 | -$15.55M derived: sum of 3 quarters · filed 2025-08-13 | -$17.93M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$10.29M 10-Q · filed 2025-05-12 | -$14.05M derived: sum of 2 quarters · filed 2025-05-12 | -$16.43M derived: sum of 3 quarters · filed 2025-05-12 | -$18.57M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$3.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$6.13M derived: sum of 2 quarters · filed 2025-03-31 | -$8.28M derived: sum of 3 quarters · filed 2025-03-31 | -$10.84M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$2.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$4.52M derived: sum of 2 quarters · filed 2024-11-14 | -$7.09M 10-Q · filed 2024-11-14 | -$11.64M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$2.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$4.71M 10-Q · filed 2024-08-08 | -$9.26M derived: sum of 3 quarters · filed 2024-08-08 | -$13.90M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$2.56M 10-Q · filed 2024-05-14 | -$7.12M derived: sum of 2 quarters · filed 2024-05-14 | -$11.75M derived: sum of 3 quarters · filed 2024-05-14 | -$16.23M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$4.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$9.19M derived: sum of 2 quarters · filed 2024-04-01 | -$13.67M derived: sum of 3 quarters · filed 2024-04-01 | -$17.03M 10-K · filed 2024-04-01 |
| 2022-09-30 | -$4.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$9.11M derived: sum of 2 quarters · filed 2023-11-14 | -$12.48M 10-Q · filed 2023-11-14 | -$16.53M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$4.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$7.84M 10-Q · filed 2023-08-14 | -$11.89M derived: sum of 3 quarters · filed 2023-08-14 | -$14.92M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$3.37M 10-Q · filed 2023-05-15 | -$7.41M derived: sum of 2 quarters · filed 2023-05-15 | -$10.44M derived: sum of 3 quarters · filed 2023-05-15 | |
| 2021-12-31 | -$4.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | -$7.08M derived: sum of 2 quarters · filed 2023-03-08 | -$9.31M 10-K · filed 2023-03-08 | |
| 2021-09-30 | -$3.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$5.26M 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | -$2.23M 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |